NCT00851461 - Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2013

Conditions

Spinobulbar Muscular AtrophyKennedy's Disease

Interventions

DRUG

Goserelin

Goserelin 10.8 mg SC every 3 months

PROCEDURE

Electrophysiologic study

Nerve conduction study Electromyogram

PROCEDURE

tissue biopsy

skin and muscle biopsy before and after treatment every year

Trial Locations (1)

Medical Genetics and Molecular Medicine Unit,, Department of Medicine, Ramathibodi Hospital, Bangkok